Press Release

EUREKA THERAPEUTICS TO PRESENT AT TWO UPCOMING VIRTUAL CONFERENCES

Emeryville, California, October 13, 2020 – Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced that it will participate virtually in two upcoming conferences in October:

TCR-based Therapies Summit

Title:                ARTEMIS® Antibody TCR T Cell Therapies for Solid Tumors

Speaker:        Cheng Liu, Ph.D., President and CEO

Date:               Tuesday, October 27, 2020

Time:               9:00 a.m. EST

Cell & Gene Therapy Bioprocessing & Commercialization

Title:               Optimizing Viral Vector Production

Speaker:        Nicole Nunez, Ph.D., Process Development Scientist

Date:               Thursday, October 22, 2020

Time:               8:00 a.m. EST

 

ABOUT EUREKA THERAPEUTICS, INC.

Eureka Therapeutics, Inc. is a privately held clinical stage biotechnology company focused on developing novel T cell therapies to treat cancers. Its core technology centers around its proprietary ARTEMIS® cell receptor platform and E-ALPHA® antibody discovery platform for the discovery and development of potentially safer and more effective T cell therapies for the treatment of solid tumors and hematologic malignancies. ET140203, the Company’s lead asset, is currently in a Phase I/II US multicenter clinical trial in patients with advanced hepatocellular carcinoma (HCC).

Eureka Therapeutics, Inc. is headquartered in the San Francisco Bay Area. For more information on Eureka, please visit www.eurekatherapeutics.com.

Contacts:

Eureka Therapeutics, Inc.
Natalie Liu
Investor Relations
510-318-9215
IR@eurekainc.com

KKH Advisors
Kimberly Ha
917-291-5744
kimberly.ha@kkhadvisors.com